Bambusa Therapeutics Inc. Company Profile
NASDAQ: BBTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Bambusa Therapeutics at a glance
Bambusa Therapeutics Inc. (NASDAQ: BBTX) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Boston, MA. Bambusa Therapeutics is led by Dr. Shanshan Xu M.B.A., M.D., Ph.D. and employs about 26 people. The company's shares have traded publicly since 2026.
At a market capitalization of $815.1 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0002044950, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Bambusa Therapeutics do?
Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis. It also develops BBT002, a long-acting bispecific antibody for respiratory and other Type 2 inflammatory diseases. Additionally, the company develops BBT003, a long-acting bispecific antibody for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company also develops BBT004 for depletion of pathogenic B cells and antibody-producing plasma cells in autoantibody-driven autoimmune diseases. The company operates in the United States, Australia, New Zealand, China, Europe, and internationally. Bambusa Therapeutics, Inc. was incorporated in 2024 and is based in Boston, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Bambusa Therapeutics Inc.
- Ticker
- NASDAQ: BBTX
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Shanshan Xu M.B.A., M.D., Ph.D.
- Employees
- 26
- Headquarters
- 22 Boston Wharf Road, Boston, MA, United States
- Phone
- (617) 848-6188
- Website
- bambusatx.com
- IPO year
- 2026
- Market cap
- $815.08M
- SEC CIK
- 0002044950
Companies similar to Bambusa Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ODTXOdyssey Therapeutics Inc. | 16.96 | -7.52% | $815.23M | vs BBTX |
| PRMEPrime Medicine Inc. | 3.55 | -7.55% | $791.62M | vs BBTX |
| MGTXMeiraGTx Holdings plc | 7.98 | -1.97% | $779.89M | vs BBTX |
| IMTXImmatics N.V. | 5.77 | -3.03% | $878.58M | vs BBTX |
| GLUEMonte Rosa Therapeutics Inc. | 8.64 | -3.03% | $738.29M | vs BBTX |
| AURAAura Biosciences Inc. | 6.87 | -1.58% | $714.99M | vs BBTX |
| SLDBSolid Biosciences Inc. | 6.25 | -2.95% | $697.57M | vs BBTX |
| ATTOAttovia Therapeutics Inc. | 15.10 | -3.08% | $690.26M | vs BBTX |